Egetis Therapeutics AB EGTX
OMXSTO · Sweden · Health Technology
SEK 9.44+0.58 (+6.55%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United StatesEgetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® RareFDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval Egetis to host a conference call and webcast for analysts and investors on Tuesday September 29 at 8:00 am CEST (2:
Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.
STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that it will participate in upcoming investor conferences in September. Cantor Global Healthcare Conference 2026Date: Friday, September 11, 2026Location: Waldorf Astoria, New YorkFormat: Fireside chat and 1-1 meetings Nicklas Westerholm, CEO, will participate in a fireside chat, 9:10-9:40 a.m. EDT (15:10-15:40 CEST). A live webcast and replay will
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.